

Review Article

Review of antibiotics therapy in ventilator associated pneumonia

Zahra Tolou-Ghamari^{1*}, Arezoo Pouredad², Zahra Foroughi²

¹Nutrition and Food Security Research Center, Deputy of Research and Technology, Isfahan University of Medical Sciences, Isfahan, Iran

²Alzahra Hospital Infectious Disease Control Committee, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract. A significant cause of morbidity and mortality was ranked as ventilator associated pneumonia (VAP). Therefore, studies based on evidence-based pharmacotherapy could help in preventing multiple drug resistance and microorganism colonization. Experts suggested an 8 or 14-21 days course of vigilant antibiotics. Therefore, to reduce toxicity and cost, this systematic review aims to investigate updated antibiotic regimens for VAP. Web of Science, PubMed and Google Scholar were searched. New-onset pneumonia that developing more than 48 hours after endotracheal intubation was defined as VAP. Regarding pulmonary recurrent or excess mortality an 8 days course antibiotic therapy showed appropriate. For treatment of resistant pathogens with high minimum inhibitory concentrations, aerosolized antimicrobials suggested more effective. Monitoring fever, procalcitonin values, C-reactive protein and PaO₂/FiO₂ should also be considered. In addition report indicated that serum procalcitonin reduces the exposure of antibiotics. A study of 100 VAP patients reported that mortality rates were significantly associated with a change in antibiotic therapy. Published result associated with 12 studies included 3571 patients with VAP, confirmed no statistical difference in all-cause mortality between monotherapy and combination therapy, clinical cure, length of stay in ICU or adverse events. Studies comparing tigecycline versus imipenem-cilastatin for clinical cure in the clinically evaluable population showed statistically significant increase in clinical cure for imipenem-cilastatin. There was no statistical difference in all-cause mortality between carbapenem and non-carbapenem therapies or adverse events, but carbapenems were associated with a statistically significant increase in the clinical cure. Treatment strategy in VAP should be considered based on pathogen reports. Vigilant attention to patient clinical status recommended to be advantageous for considering limited spectrum antibiotics.

Keywords: Antibiotics, ventilator, pathogen, pneumonia, pharmacotherapy.

Introduction

Due to increasing in the prevalence of healthcare associated infections, mortality and antibiotic resistance is increasing additionally. Therefore, antibiotics prescription is a key argument to control antibiotic resistance [1]. As an infectious event nosocomial infections (NIs) occur two days after admission without evidence that the pathogen was already in the incubation phase [2]. Ventilator associated pneumonia as a significant contributor ranked as the first cause of NIs that needs antibiotic therapy based on the patient's risk of colonization by an organism with multidrug resistance. It is well known that higher mortality and longer hospital stay associated with inappropriate initial antimicrobial treatment [3, 4]. Publication reported the commonly pathogens that were associated with multiple-drug resistant called acinetobacter baumannii and klebsiella pneumonia that are responsible for 80% of NIs comprising urinary tract infections, meningitis, pneumonia, wound infections and bacteremia. [5, 6]. Regarding acinetobacter baumannii cefoperazone sulbactam recommended to be useful with further evaluation regarding effectiveness [7].

Regarding carbapenem-resistant K. pneumonia bacteriophage therapy as an alternative method for respiratory infections, liver abscesses and bacteremia was suggested [8, 9, 10]. With a reported incidence of 4% associated with methicillin-resistant Staphylococcus aureus, in-hospital mortality rate estimated to be 31%, when methicillin-resistant Staphylococcus aureus is the causative pathogen in pneumonia [11]. For patients with ventilator-associated pneumonia (VAP), antibiotic therapy for seven-day course was recommended [12]. Antimicrobial resistance, Clostridiodes difficile infection, allergic reaction. QTc prolongation and thrombocytopenia could be a result of inappropriate antibiotic therapy [13]. Therefore, in intensive care unit a major point to control antimicrobial resistance is to reduce the use of antibiotics [14-17]. This study aims to evaluate different strategy of antibiotic therapy in VAP.

Materials and Methods

We performed an electronic search of the relevant literature with no language restrictions in: PubMed/Medline and Web of science. With searching "Antibiotics Therapy in

*Corresponding author: Professor Zahra Tolou_Ghamari
(toloeghamari@pharm.mui.ac.ir)

Ventilator Associated Pneumonia” there were in Web of Science, 2052 articles during 2023 to 1991 and in PubMed 2538 articles during 2023 to 1990. The risk of bias assessment of the studies and data extraction and analysis of results was carried out by the clinical pharmacist Z.T and doubts in this step were resolved by asking from clinical experts.

Results

The first cause of health care-associated infections, is ventilator associated pneumonia in intensive care unit in which respiratory tract infections are responsible for greater than 50% of antibiotic therapy [18]. Regarding immunocompromised patients gram negative bacteria are the most commonly isolated pathogens in VAP that needs antibiotic management [19]. World Health Organization ranked acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumonia, Escherichia coli and Enterobacter spp. as a critical group of pathogens that requires new antibiotics [20]. A recent publication recommended against adding polymyxin B to the high-dose tigecycline regimen in treating pneumonia caused by carbapenem-resistant *K. pneumoniae* and *A. baumannii* [21]. Vasopressor infusion, acid suppression, delayed luminal nutrition and antibiotic administration could affect the proportion of potentially pathogenic microbes and exacerbate the clinical conditions in patients at intensive care unit [22]. In this situation dysbiosis could be a result of change in gut microbiota due to factors such as nutrition support, the presence of infection, modified gastrointestinal transit and antimicrobial exposure [23]. For prediction of survival, and outcome in those with VAP, measurement of procalcitonin at onset and day 4 of treatment recommended [24]. In this regard, however for the suspicion of sepsis procalcitonin might be superior to c reactive protein, but it should not be used to guide antimicrobial prescription [25, 26].

Regarding many available antibiotics, resistance due to infection with the gram negative opportunistic pathogen *Pseudomonas aeruginosa* could cause high morbidity and mortality in VAP [27]. Hydrolysis mediated by the production of degrading enzymes, decreased membrane permeability, drug efflux pump, alteration of drug target are the most important factors associated with antibiotic resistance. Against some of the carbapenem-resistant Enterobacteriaceae, especially *Klebsiella pneumoniae* carbapenemase producers, ceftazidime-avibactam, imipenem-relebactam and meropenem-vaborbactam reported to have a potent activity. In addition, ceftazidime-avibactam, ceftolozane-tazobactam, imipenem-relebactam and cefiderocol have potent activity against multidrug-resistant *Pseudomonas aeruginosa*. [28-30]. Therefore, the site of infection, time of onset and previous length of stay, previous antibiotic therapy, and known multi-resistant organism colonization should always be considering in association with management of antibiotic therapy [31].

Discussion

Ventilator associated pneumonia as a source of morbidity and mortality, was reported as the most common nosocomial infections in both adults and children stayed at

the intensive care unit [32, 33]. Publication predicted that approximately 10 million people could die each year because of antimicrobial resistance by year 2050 [34]. Therefore, in order to control specific patients' conditions, management of antibiotics and dosage adjustments should be based on inter- and intra-individual variations.

Comparing short versus long antibiotic therapy showed different outcome regarding antimicrobial resistance and adverse effects. Associated with different sites of infections and different infections with gram-negative bacilli not generalization can be made [35]. Cefotaxim was reported as a protective antibiotic against wild-type AmpC-producing Enterobacteriales [36]. Cell wall synthesis of bacteria could be inhibited by the beta-lactam imipenem [37-38]. For differentiation and detection of pathogens, monitoring of volatile organic compounds concentrations' may indicate emerging pneumonia [39]. Administration of aerosolized amikacin in combination with systemic antimicrobial therapy improving the outcomes of patients with VAP, resulting effective initial microbial reduction in the sputum, decreases the generation of reactive oxygen species in leukocyte and declines VAP-mediated cell membrane changes of circulating leukocytes [40].

As the most antibiotic poorly penetrating into the lung, therefore combination of cefiderocol and fosfomycin suggested as a useful strategy in patients with VAP caused by carbapenem-resistant *Acinetobacter baumannii*. However, in this situation intravenous colistin recommended not to be useful [41-42]. With a high rate of recurrence (25-50%) and mortality (14-50%), predicting infection recurrence following procalcitonin guided antibiotic discontinuation in VAP, tracheal secretions and simplified clinical pulmonary infection score could be used [43].

For patients with clinically suspicion of VAP, early administration of an adequate broad spectrum antibiotics is associated with higher morbidity and mortality and the rate of superinfection in those with prolonged course of antibiotic therapy [44]. When the MICs are ≤ 8 mg/L, for treating nosocomial pneumonia by extended-spectrum β -lactamase-producing *K. pneumoniae* piperacillin/tazobactam could be an effective alternative to carbapenems [45]. For multidrug-resistant Gram-negative bacteria pneumonia, nebulized colistin sulfate as an adjuvant supportive treatment for intravenous antibiotics maybe can improve clinical efficacy and has high safety [46]. Finally, prolonged antibiotics are associated with toxicity, selection for resistant organisms and secondary infections such as *Clostridioides difficile* colitis [47].

Conclusion

There is need for a novel evidence based antibiotic treatment strategies for patients with VAP, as it is the second leading cause of death associated with nosocomial infections. Regarding to the rate of reported infection due to the inter- and intra-individual variations, achieving a delicate balance for antibiotic therapy recommended. The duration of antibiotic therapy for patients with VAP caused by *Acinetobacter baumannii*, *Klebsiella pneumoniae* and *Pseudomonas aeruginosa* need further attention.

Conflict of Interest

The Authors declare that there is no conflict of interest.

Acknowledgements

Thanks to Isfahan University of Medical Sciences, Isfahan, Iran.

References

1. Choudhuri AH, Chakravarty M, Uppal R. Epidemiology and characteristics of nosocomial infections in critically ill patients in a tertiary care Intensive Care Unit of Northern India. *Saudi J Anesth* 11: 402-407, 2017.
2. Rosenthal VD, Bat-Erdene I, Gupta D, Belkebir S, Rajhans P, Zand F, et al. International Nosocomial Infection Control Consortium (INICC) report, data summary of 45 countries for 2012–2017: Device-associated module. *Am J Infect Control* 148:423–432, 2020.
3. Zand F, Vakili H, Asmariyan N, Masjedi M, Sabetian G, Nikandish R, et al. Unintended impact of COVID-19 pandemic on the rate of catheter related nosocomial infections and incidence of multiple drug resistance pathogens in three intensive care units not allocated to COVID-19 patients in a large teaching hospital. *BMS Infect Dis* 23: 11, 2023.
4. Lauren E Arthur, Russell S Kizor, Adrian G Selim, Mieke L van Driel, Leonardo Seoane. Antibiotics for ventilator-associated pneumonia. *Cochrane Database of Systematic Reviews Review – Intervention 2016 Version history*.
5. Püntener-Simmen S, Zurfluh K, Schmitt S, Stephan R, Nüesch-Inderbinen M. Phenotypic and Genotypic Characterization of Clinical Isolates Belonging to the *Acinetobacter calcoaceticus*-*Acinetobacter baumannii* (ACB) Complex Isolated From Animals Treated at a Veterinary Hospital in Switzerland. *Front Vet Sci* 6:17, 2019.
6. Kogilathota Jagirdhar GS, Rama K, Reddy ST, Pattanaik H, Qasba RK, Elmati PR, Kashyap R, Schito M, Gupta N. Efficacy of Cefoperazone Sulbactam in Patients with *Acinetobacter* Infections: A Systematic Review of the Literature. *Antibiotics (Basel)* 12:582, 2023.
7. Hafiz TA, Alghamdi SS, Mubarak MA, Alghamdi SSM, Althaybi A, Aldawood E, Alotaibi F. A two-year retrospective study of multidrug-resistant *Acinetobacter baumannii* respiratory infections in critically ill patients: Clinical and microbiological findings. *J Infect Public Health* 16:313-319, 2023.
8. Mohammadi M, Saffari M, Siadat SD, Hejazi SH, Shayestehpour M, Motallebi M, Eidi M. Isolation, characterization, therapeutic potency, and genomic analysis of a novel bacteriophage vB_KshKPC-M against carbapenemase-producing *Klebsiella pneumoniae* strains (CRKP) isolated from Ventilator-associated pneumoniae (VAP) infection of COVID-19 patients. *Ann Clin Microbiol Antimicrob* 22:18, 2023.
9. Wu N, Zhu T. Potential of therapeutic bacteriophage in nosocomial infection management. *Front Microbiol* 12: 638094, 2021.
10. Al-Ishaq RK, Skariah S, Büsselberg D. Bacteriophage treatment: Critical evaluation of its application on World Health Organization priority Pathogens. *Viruses* 13:51, 2021.
11. Doan K, Smoke S. Antibiotic de-escalation in pneumonia with pharmacist education and ordering of methicillin-resistant *Staphylococcus aureus* nasal swabs. *Eur J Hosp Pharm* ejhpharm-2022-003504, 2023.
12. Meizoso JP, Sauaia A, Namias N, Manning RJ, Pieracci FM. Duration of antibiotic therapy for early vap trial: study protocol for a surgical infection society multicenter, pragmatic, randomized clinical trial of four versus seven days of definitive antibiotic therapy for early ventilator-associated pneumonia in surgical patients. *Surg Infect (Larchmt)* 24:163-168, 2023.
13. Adams J, Ferguson K, Hirschy R, Konopka E, Meckel J, Benanti G, Kuhrau S, Albarillo F, Chang K, Santarossa M, Sapozhnikov J, Hoff B, Rech MA. Antimicrobial stewardship techniques for critically ill patients with pneumonia. *Antibiotics (basel)* 12:295, 2023.
14. Foucrier A, Roquilly A, Bachelet D, Martin-Loeches I, Bougle A, Timsit JF, Montravers P, Zahar JR, Eloy P, Weiss E; ASPIC study group. Antimicrobial stewardship for ventilator associated pneumonia in intensive care (the ASPIC trial): study protocol for a randomised controlled trial. *BMJ Open* 13:e065293, 2023.
15. De Waele JJ, Akova M, Antonelli M, et al. Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance. *Intensive Care Med* 44:189–196, 2018
16. Ashraf M, Ostrosky-Zeichner L. Ventilator-associated pneumonia: a review. *Hosp Pract (1995)* 40:93-105, 2012.
17. Bergmans DC, Bonten MJ, Gaillard CA, van Tiel FH, van der Geest S, de Leeuw PW, Stobberingh EE. Indications for antibiotic use in ICU patients: a one-year prospective surveillance. *J Antimicrob Chemother* 39:527-535, 1997.
18. Daghmouri MA, Dudoignon E, Chaouch MA, Baekgaard J, Bougle A, Leone M, Deniau B, Depret F. Comparison of a short versus long-course antibiotic therapy for ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials. *EClinicalMedicine* 58:101880, 2023.
19. Kreitmann L, Gaudet A, Nseir S. Ventilator-Associated Pneumonia in Immunosuppressed Patients. *Antibiotics (Basel)* 12:413, 2023.
20. Tacconelli E., Carrara E., Savoldi A., Harbarth S., Mendelson M., Monnet D.L., Pulcini C., Kahlmeter G., Kluytmans J., Carmeli Y., et al. Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect. Dis* 18:318-327, 2018.
21. Zha L, Zhang X, Cheng Y, Xu Q, Liu L, Chen S, Lu Z, Guo J, Tefsen B. Intravenous Polymyxin B as Adjunctive Therapy to High-Dose Tigecycline for the Treatment of Nosocomial Pneumonia Due to Carbapenem-Resistant *Acinetobacter baumannii* and *Klebsiella pneumoniae*: A Propensity Score-Matched Cohort Study. *Antibiotics (Basel)* 12:273, 2023.
22. May AK. Host Microbiome Threats in the Intensive Care Unit. *Surg Infect (Larchmt)* 24:276-283, 2023.

23. Gibson GA, Owen EJ. Non-Antibiotic Approaches to Infection that Preserve the Microbiome in Critically Ill Patients. *Surg Infect (Larchmt)* 24:284-291, 2-23.
24. Póvoa P, Coelho L, Dal-Pizzol F, Ferrer R, Huttner A, Conway Morris A, Nobre V, Ramirez P, Rouze A, Salluh J, Singer M, Sweeney DA, Torres A, Waterer G, Kalil AC. How to use biomarkers of infection or sepsis at the bedside: guide to clinicians. *Intensive Care Med* 49:142-153, 2023.
25. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. *Intensive Care Med* 47:1181-1247, 2021.
26. Layios N, Lambermont B, Canivet JL, et al. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. *Crit Care Med* 40:2304-2309, 2012.
27. Wood SJ, Kuzel TM, Shafikhani SH. *Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics*. *Cells* 12:199, 2023.
28. Arzanlou M, Chai WC, Venter H. Intrinsic, adaptive and acquired antimicrobial resistance in Gram-negative bacteria. *Essays Biochem* 61:49-59, 2017.
29. Bassetti M, Giacobbe DR, Robba C, et al. Treatment of extended-spectrum beta-lactamases infections: what is the current role of new beta-lactams/beta-lactamase inhibitors? *Curr Opin Infect Dis* 33:474-481, 2020.
30. Vena A, Castaldo N, Bassetti M. The role of new beta-lactamase inhibitors in Gram-negative infections. *Curr Opin Infect Dis* 32:638-646, 2019.
31. Zahar JR, Timsit JF. Risk stratification for selecting empiric antibiotherapy during and after COVID-19. *Curr Opin Infect Dis* 35:605-613, 2022.
32. Debbagh F, Ben Houmich T, Guennouni M, Sahraoui H, Hanchi AL, Mouaffak Y, Younous S, Soraa N. Evaluation PCR panel of the FilmArray® pneumonia plus for pathogen detection of ventilator-associated pneumonia in children and its impact on therapeutic management. *Iran J Microbiol* 15:19-26, 2023.
33. Harrell KN, Lee WB, Rooks HJ, Briscoe WE, Capote W, Dart BW 4th, Hunt DJ, Maxwell RA. Early pneumonia diagnosis decreases ventilator-associated pneumonia rates in trauma population. *J Trauma Acute Care Surg* 94:30-35, 2023.
34. Assefa M. Multi-drug resistant Gram-negative bacterial pneumonia: etiology, risk factors, and drug resistance patterns. *Pneumonia* 14:4, 2022.
35. Vieceli T, Rello J. Optimization of antimicrobial prescription in the hospital. *Eur J Intern Med* 106:39-44, 2022.
36. Mounier R, Le Guen R, Woerther PL, Nacher M, Bonnefon C, Mongardon N, Langeron O, Levesque E, Couffin S, Houcke S, Wolff M, Roujansky A, Schimpf C, Mekontso Dessap A, Cook F, Razazi K, Kallel H. Clinical outcome of wild-type AmpC-producing Enterobacterales infection in critically ill patients treated with β -lactams: a prospective multicenter study. *Ann Intensive Care* 12:107, 2022.
37. Pajot O, Lakhal K, Lambert J, Gros A, Bruel C, Boulain T, Garot D, Das V, Timsit JF, Cerf C, Souweine B, Chaffaut C, Mentec H, Zahar JR, Mira JP, Jullien V. Empirical Antibiotic Therapy for Gram-Negative Bacilli Ventilator-Associated Pneumonia: Observational Study and Pharmacodynamic Assessment. *Antibiotics (Basel)* 11:1664, 2022.
38. Dwyer D. J., Belenky P. A., Yang J. H., Cody MacDonald I., Martell J. D., Takahashi N., et al. Antibiotics induce redox-related physiological alterations as part of their lethality. *Proc. Natl. Acad. Sci. U. S. A.* 111, E2100-E2109, 2014.
39. Filipiak W, Żuchowska K, Marszałek M, Depka D, Bogiel T, Warmuzińska N, Bojko B. GC-MS profiling of volatile metabolites produced by *Klebsiella pneumoniae*. *Front Mol Biosci* 9:1019290, 2022.
40. Levchenko B, Nazarchuk O, Dmytriiiev D, Bahniuk N, Melnychenko M, Dmytriiiev K. Adjunctive inhaled amikacin in infants with Ventilator-Associated Pneumonia optimizes the complex antimicrobial therapy: pilot study. *Acta Biomed* 94:e2023084, 2023.
41. Russo A, Bruni A, Gulli S, Borrazzo C, Quirino A, Lionello R, Serapide F, Garofalo E, Serraino R, Romeo F, Marascio N, Matera G, Longhini F, Trecarichi EM, Torti C. Efficacy of cefiderocol- versus colistin-containing regimen for treatment of bacteremic ventilator-associated pneumonia caused by carbapenem-resistant *Acinetobacter baumannii* in COVID-19 patients. *Int J Antimicrob Agents* 62:106825, 2023.
42. Oliva A, Al Ismail D, Arcari G, Miele MC, Casali E, Sacco F, Volpicelli L, De Angelis M, Mascellino MT, Cancelli F, Raponi G, Carattoli A, Venditti M. Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing *Klebsiella pneumoniae*: analysis of cases and evaluation of in-vitro activity of fosfomycin-containing combinations. *J Glob Antimicrob Resist* S2213-7165(23)00058-59, 2023.
43. Wang Q, Hou D, Wang J, An K, Han C, Wang C. Procalcitonin-guided antibiotic discontinuation in ventilator-associated pneumonia: a prospective observational study. *Infect Drug Resist* 12:815-824, 2019.
44. Muscedere JG, Shorr AF, Jiang X, Day A, Heyland DK; Canadian Critical Care Trials Group. The adequacy of timely empiric antibiotic therapy for ventilator-associated pneumonia: an important determinant of outcome. *J Crit Care* 27:322.e7-14, 2012.
45. Zha L, Li X, Ren Z, Zhang D, Zou Y, Pan L, Li S, Chen S, Tefsen B. Pragmatic Comparison of Piperacillin/Tazobactam versus Carbapenems in Treating Patients with Nosocomial Pneumonia Caused by Extended-Spectrum β -Lactamase-Producing *Klebsiella pneumoniae*. *Antibiotics (Basel)* 11:1384, 2022.
46. Bao XL, Tao T, Tang N, Wang YZ, Liao XQ, Huang LL, Ji JJ, Chen X. Efficacy and safety of adjunctive nebulized colistin sulfate for multidrug-resistant Gram-negative bacteria pneumonia: a retrospective comparative cohort study. *Ann Palliat Med* 11:2939-2951, 2022.
47. Imlay H, Spellberg B. Shorter is better: The case for short antibiotic courses for common infections in solid organ transplant recipients. *Transpl Infect Dis* 24:e13896, 2022.